Sun, Yuping

ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.

Wang, J., Duan, J., Xing, L., Sun, Y., Guo, W., Wang, H., Chen, J., Han, L., Liu, B., Wang, Q., et al. (2023) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 28

Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial

Xiong, A., Ren, S., Liu, H., Miao, L., Wang, L., Chen, J., Li, W., Li, R., Wang, X., Lu, Z., et al. (2022) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 20

Promising early results of MHB088C (B7-H3 ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from a phase 1/2 multicenter study.

Shen, L., Meng, X., Sun, Y., Zhao, Y., Huang, H., Han, L., Zhang, Z., Chang, F., Ji, Y., Wu, G., et al. (2025) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 4